• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性进行性多发性硬化症的医疗资源利用情况。

Healthcare resources utilisation in primary progressive multiple sclerosis.

机构信息

CORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.

Health Care Department, CINECA-Interuniversity Consortium, Casalecchio di Reno, Bologna, Italy.

出版信息

Neurol Sci. 2018 Jul;39(7):1169-1174. doi: 10.1007/s10072-018-3404-4. Epub 2018 Apr 10.

DOI:10.1007/s10072-018-3404-4
PMID:29637449
Abstract

Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This study was aimed to evaluate the burden of PPMS in Italy with healthcare resources utilisation and costs for Italian National Health System (INHS). A 2-year cross-sectional analysis of real-world data collected in the ARCO database, covering > 10 million Italian inhabitants, was performed. From a cohort of patients affected by MS in 2014, those supposedly affected by PPMS were defined by the concurrent matching of absence of disease-modifying treatments and use of rehabilitation services. Any other drug prescriptions, outpatient services and hospitalisations were analysed in 2015 for each subject. The average annual cost per patient was provided both for each expenditure item and by integrating these. Of 13,253,591 inhabitants, 18,453 resulted affected by MS (prevalence 139 × 100,000). Of these, 1849 agreed with additional criteria to identify PPMS (10% of MS population). The 26.8% of these experienced at least one admission in 1 year, 97.3% used at least one outpatient service and 94.3% received at least one reimbursed drug. In the perspective of INHS, PPMS generated an average annual cost of € 3783 per person: 49% for hospitalisations, 28% for outpatient services and 23% for drugs. This study provides a reliable estimation of the PPMS burden in Italy, in terms of healthcare utilisation and direct costs. These findings could be useful to estimate the changes in health expenditure following the incoming of new drugs to treat PPMS with increase of pharmaceutical cost and potential decrease of rehabilitation and hospitalisation costs.

摘要

原发性进展型多发性硬化症(PPMS)的流行病学数据较为匮乏。本研究旨在评估意大利 PPMS 的疾病负担,分析意大利国家卫生系统(INHS)的医疗资源利用和成本情况。本研究通过 ARCO 数据库收集了 2014 年超过 1000 万意大利居民的真实世界数据,采用了为期 2 年的回顾性横断面分析。在这一队列中,对患有 MS 的患者进行分析,同时考虑到缺乏疾病修正治疗和使用康复服务,将这些患者定义为可能患有 PPMS 的患者。对每位患者,在 2015 年分析了其他任何药物处方、门诊服务和住院情况。按每个支出项目和整合这些项目分别提供每位患者的平均年度费用。在 1325.3591 万居民中,有 18453 人患有 MS(发病率为 139×100000)。其中,1849 人符合识别 PPMS 的附加标准(MS 人群的 10%)。在这些患者中,26.8%的患者在 1 年内至少经历过一次住院治疗,97.3%的患者至少使用过一次门诊服务,94.3%的患者至少接受过一种报销药物。从 INHS 的角度来看,PPMS 每人每年产生 3783 欧元的平均费用:49%用于住院治疗,28%用于门诊服务,23%用于药物治疗。本研究提供了意大利 PPMS 负担的可靠估计,包括医疗资源利用和直接成本。这些发现可能有助于估计随着治疗 PPMS 的新药的引入,医疗支出的变化,从而增加药品成本和潜在降低康复和住院成本。

相似文献

1
Healthcare resources utilisation in primary progressive multiple sclerosis.原发性进行性多发性硬化症的医疗资源利用情况。
Neurol Sci. 2018 Jul;39(7):1169-1174. doi: 10.1007/s10072-018-3404-4. Epub 2018 Apr 10.
2
Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.澳大利亚原发性进行性多发性硬化症的社会成本,以及一种假设的疾病修正治疗可能延迟疾病进展的经济影响。
J Med Econ. 2021 Jan-Dec;24(1):140-149. doi: 10.1080/13696998.2021.1872585.
3
HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.HR+/HER2- 转移性乳腺癌:来自大型意大利真实世界数据库的流行病学、处方模式、医疗资源利用和成本。
Clin Drug Investig. 2019 Oct;39(10):945-951. doi: 10.1007/s40261-019-00822-4.
4
Healthcare usage and economic impact of non-treated obesity in Italy: findings from a retrospective administrative and clinical database analysis.意大利未治疗肥胖症的医疗保健使用情况及经济影响:一项回顾性行政与临床数据库分析的结果
BMJ Open. 2017 Feb 24;7(2):e013899. doi: 10.1136/bmjopen-2016-013899.
5
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.基于意大利某地区真实世界数据的观察性分析:憩室疾病的经济负担。
Dig Liver Dis. 2017 Sep;49(9):1003-1008. doi: 10.1016/j.dld.2017.05.024. Epub 2017 Jun 8.
6
Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation--an Italian perspective.慢性静脉功能不全:医疗改革对治疗和住院费用的影响——意大利视角
Curr Med Res Opin. 2003;19(8):761-9. doi: 10.1185/030079903125002559.
7
A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean.关于拉丁美洲和加勒比地区原发性进行性多发性硬化症流行病学的系统评价。
Mult Scler Relat Disord. 2018 May;22:1-7. doi: 10.1016/j.msard.2018.02.024. Epub 2018 Feb 24.
8
[Burden of diverticular disease: an observational analysis based on Italian real-world data.].[憩室病负担:基于意大利真实世界数据的观察性分析。]
Recenti Prog Med. 2018 Jan;109(1):15-24. doi: 10.1701/2848.28749.
9
Osteoporosis: Economic Burden of Disease in Italy.骨质疏松症:意大利的疾病经济负担。
Clin Drug Investig. 2020 May;40(5):449-458. doi: 10.1007/s40261-020-00904-8.
10
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.大麻素用于进行性炎症性脑病(CUPID)试验:一项随机双盲安慰剂对照平行组多中心试验及大麻素延缓多发性硬化症进展的经济学评估。
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

引用本文的文献

1
Economic burden of secondary progressive multiple sclerosis: DISCOVER study.继发进展型多发性硬化的经济负担:DISCOVER研究
BMC Health Serv Res. 2025 Apr 10;25(1):525. doi: 10.1186/s12913-025-12592-1.
2
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study.德国在使用奥瑞珠单抗治疗原发性进行性多发性硬化症(PPMS)患者之前的最佳支持性护理:RETRO PPMS研究的最终结果。
J Cent Nerv Syst Dis. 2024 Oct 23;16:11795735241296001. doi: 10.1177/11795735241296001. eCollection 2024.
3
Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database.

本文引用的文献

1
Multiple Sclerosis.多发性硬化症
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
2
New Inroads Against Multiple Sclerosis.对抗多发性硬化症的新进展
JAMA. 2018 Jan 2;319(1):9-11. doi: 10.1001/jama.2017.14033.
3
Monitoring compliance with standards of care for chronic diseases using healthcare administrative databases in Italy: Strengths and limitations.利用意大利医疗管理数据库监测慢性病护理标准的依从性:优势与局限
来自意大利一个大型理赔数据库的高危患者带状疱疹的处方、住院情况及费用模式。
Glob Reg Health Technol Assess. 2020 Sep 10;7:66-71. doi: 10.33393/grhta.2020.2026. eCollection 2020 Jan-Dec.
4
[Not Available].[无可用内容]
Glob Reg Health Technol Assess. 2021 Feb 5;8:1-7. doi: 10.33393/grhta.2021.2178. eCollection 2021 Jan-Dec.
5
HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.HR+/HER2- 转移性乳腺癌:来自大型意大利真实世界数据库的流行病学、处方模式、医疗资源利用和成本。
Clin Drug Investig. 2019 Oct;39(10):945-951. doi: 10.1007/s40261-019-00822-4.
6
A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years.一项关于曲坦类药物治疗偏头痛未满足医疗需求的真实世界研究:来自意大利大样本人群长达两年的患病率、预防性治疗和曲坦类药物使用调整。
J Headache Pain. 2019 Jun 27;20(1):74. doi: 10.1186/s10194-019-1027-7.
7
Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.复发缓解型和原发进展型多发性硬化症的疾病修正治疗:成本效用分析。
CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9.
PLoS One. 2017 Dec 12;12(12):e0188377. doi: 10.1371/journal.pone.0188377. eCollection 2017.
4
New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.欧洲多发性硬化症负担与成本的新见解:意大利的结果
Mult Scler. 2017 Aug;23(2_suppl):104-116. doi: 10.1177/1352458517708176.
5
Estimated prevalence of multiple sclerosis in Italy in 2015.2015年意大利多发性硬化症的估计患病率。
Neurol Sci. 2017 Mar;38(3):473-479. doi: 10.1007/s10072-016-2801-9. Epub 2016 Dec 31.
6
Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis.意大利骨质疏松症患者对阿仑膦酸或利塞膦酸治疗的依从性,无论是否联合钙和维生素D治疗及其相关决定因素
Patient Prefer Adherence. 2016 Apr 19;10:523-30. doi: 10.2147/PPA.S95634. eCollection 2016.
7
Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.意大利拉齐奥地区多发性硬化症的患病率:基于健康信息系统的算法应用
J Neurol. 2016 Apr;263(4):751-9. doi: 10.1007/s00415-016-8049-8. Epub 2016 Feb 17.
8
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.原发性进行性多发性硬化症的口服芬戈莫德(INFORMS):一项 3 期、随机、双盲、安慰剂对照试验。
Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.
9
The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database.心力衰竭的真实世界证据:来自 ARNO 数据库的 41413 例患者的研究结果。
Eur J Heart Fail. 2016 Apr;18(4):402-10. doi: 10.1002/ejhf.471. Epub 2016 Jan 11.
10
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.审视多发性硬化症患者未被满足的需求。
Am Health Drug Benefits. 2015 Nov;8(8):426-31.